Clinical Trials Logo

Clinical Trial Summary

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of production. Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD, but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care. In order to investigate the effectiveness of rivastigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06382649
Study type Interventional
Source Washington University School of Medicine
Contact Kevin Baumgartner, MD
Phone 3142731109
Email baumgartner.k@wustl.edu
Status Not yet recruiting
Phase Phase 2
Start date June 2024
Completion date July 2026

See also
  Status Clinical Trial Phase
Completed NCT06447259 - Drug Burden Index is Associated With Malnutrition in Community-dwelling Dementia Patients
Recruiting NCT04233541 - Frailty Status and Increased Risk for Falls
Not yet recruiting NCT06399679 - Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium Phase 2